AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:10:00Z
Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Income before tax | 1662.00M | 1783.00M | 2242.00M | 985.00M | 1163.00M |
Minority interest | - | - | - | - | - |
Net income | 1484.00M | 1779.00M | 2092.00M | 874.00M | 1220.00M |
Selling general administrative | 4719.00M | 4709.00M | 1.00M | -7.00000M | 2.00M |
Selling and marketing expenses | - | - | 4867.00M | 4325.00M | 4332.00M |
Gross profit | 8170.00M | 8477.00M | 9427.00M | 7577.00M | 8288.00M |
Reconciled depreciation | 2288.00M | 2229.00M | 2273.00M | 2154.00M | 2253.00M |
Ebit | 2427.00M | 2282.00M | 2799.00M | 1484.00M | 1760.00M |
Ebitda | 4715.00M | 4602.00M | 5169.00M | 3976.00M | 4535.00M |
Depreciation and amortization | 2288.00M | 2320.00M | 2370.00M | 2492.00M | 2775.00M |
Non operating income net other | - | -101.00000M | -88.00000M | 30.00M | - |
Operating income | 2111.00M | 2282.00M | 2799.00M | 1484.00M | 1760.00M |
Other operating expenses | 16948.00M | 16395.00M | 17265.00M | 15324.00M | 15050.00M |
Interest expense | 452.00M | 398.00M | 469.00M | 528.00M | 639.00M |
Tax provision | 132.00M | 148.00M | 150.00M | 111.00M | -7.00000M |
Interest income | 49.00M | 16.00M | 460.00M | 501.00M | 626.00M |
Net interest income | -403.00000M | -382.00000M | -460.00000M | -521.00000M | -627.00000M |
Extraordinary items | -46.00000M | 144.00M | 488.00M | 522.00M | 50.00M |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 132.00M | 148.00M | 150.00M | 111.00M | -57.00000M |
Total revenue | 19372.00M | 18870.00M | 20248.00M | 17117.00M | 17290.00M |
Total operating expenses | 5746.00M | 6002.00M | 6444.00M | 5784.00M | 6048.00M |
Cost of revenue | 11202.00M | 10393.00M | 10821.00M | 9540.00M | 9002.00M |
Total other income expense net | -359.00000M | -499.00000M | -557.00000M | -499.00000M | -597.00000M |
Discontinued operations | - | 144.00M | 144.00M | 144.00M | 144.00M |
Net income from continuing ops | 1530.00M | 1635.00M | 2092.00M | 874.00M | 1233.00M |
Net income applicable to common shares | 1424.00M | 1689.00M | 2002.00M | 767.00M | 1081.00M |
Preferred stock and other adjustments | - | 90.00M | 90.00M | 107.00M | - |
Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Total assets | 52780.00M | 52934.00M | 53866.00M | 54012.00M | 51842.00M |
Intangible assets | 552.00M | 12311.00M | 12784.00M | 13813.00M | 14977.00M |
Earning assets | - | - | - | - | - |
Other current assets | 1380.00M | 1712.00M | 1071.00M | 891.00M | 1110.00M |
Total liab | 26984.00M | 27633.00M | 30189.00M | 30237.00M | 30665.00M |
Total stockholder equity | 25796.00M | 25301.00M | 23677.00M | 23775.00M | 21177.00M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 5500.00M | 3933.00M | 6126.00M | 5116.00M | 4289.00M |
Common stock | 371.00M | 365.00M | 365.00M | 365.00M | 347.00M |
Capital stock | - | 367.00M | 367.00M | 367.00M | 349.00M |
Retained earnings | 15535.00M | 15157.00M | 13826.00M | 12791.00M | 12913.00M |
Other liab | - | 5936.00M | 6453.00M | 6851.00M | 6948.00M |
Good will | 24522.00M | 24621.00M | 23901.00M | 23620.00M | 23376.00M |
Other assets | 2078.00M | 1.00M | -1.00000M | 1269.00M | 1.00M |
Cash | 1416.00M | 1006.00M | 2283.00M | 2825.00M | 536.00M |
Cash and equivalents | 1416.00M | 1006.00M | 2283.00M | 2825.00M | 536.00M |
Total current liabilities | 6641.00M | 7811.00M | 6626.00M | 5823.00M | 5598.00M |
Current deferred revenue | -1641.00000M | - | -1793.00000M | -1355.00000M | -1092.00000M |
Net debt | 14463.00M | 15059.00M | 15327.00M | 15106.00M | 18854.00M |
Short term debt | 1141.00M | 2179.00M | 500.00M | 707.00M | 1309.00M |
Short long term debt | 1141.00M | 2179.00M | 500.00M | 707.00M | 1309.00M |
Short long term debt total | 15879.00M | 16065.00M | 17610.00M | 17931.00M | 19390.00M |
Other stockholder equity | 11438.00M | 11265.00M | 11572.00M | 13165.00M | 10198.00M |
Property plant equipment | 6557.00M | 6012.00M | 6393.00M | 5923.00M | 5659.00M |
Total current assets | 8676.00M | 8141.00M | 8838.00M | 8969.00M | 6644.00M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | -11631.00000M | -13007.00000M | -13671.00000M | -17275.00000M |
Short term investments | 8.00M | 8.00M | 12.00M | 20.00M | 30.00M |
Net receivables | 2534.00M | 2191.00M | 2497.00M | 2398.00M | 2335.00M |
Long term debt | 14738.00M | 13886.00M | 17110.00M | 17224.00M | 18081.00M |
Inventory | 3273.00M | 3224.00M | 2866.00M | 2743.00M | 2579.00M |
Accounts payable | 1641.00M | 1699.00M | 1793.00M | 1355.00M | 1092.00M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -1548.00000M | -1488.00000M | -2088.00000M | -2548.00000M | -2283.00000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 365.00M | 365.00M | 365.00M | 347.00M |
Preferred stock total equity | - | 2.00M | 2.00M | 2.00M | - |
Retained earnings total equity | - | 15157.00M | 13826.00M | 12791.00M | - |
Treasury stock | - | -8330.00000M | -7723.00000M | -6138.00000M | -6190.00000M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 2078.00M | -3361.00000M | 1952.00M | 1687.00M | 1075.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 44104.00M | 44792.00M | 45029.00M | 45043.00M | 45197.00M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | 14738.00M | 13886.00M | 17110.00M | 17224.00M | 18081.00M |
Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
Investments | -716.00000M | -3231.00000M | -1880.00000M | -1232.00000M | -741.00000M |
Change to liabilities | - | -473.00000M | 687.00M | 205.00M | -470.00000M |
Total cashflows from investing activities | -716.00000M | -3220.00000M | -1880.00000M | -1232.00000M | -741.00000M |
Net borrowings | - | -78.00000M | -243.00000M | -1760.00000M | -2035.00000M |
Total cash from financing activities | -1957.00000M | -591.00000M | -3306.00000M | 22.00M | -3224.00000M |
Change to operating activities | - | -1394.00000M | 282.00M | 81.00M | 299.00M |
Net income | 1530.00M | 1779.00M | 2092.00M | 874.00M | 1220.00M |
Change in cash | 322.00M | -1233.00000M | -525.00000M | 2327.00M | -646.00000M |
Begin period cash flow | 1159.00M | 2392.00M | 2917.00M | 590.00M | 1236.00M |
End period cash flow | 1481.00M | 1159.00M | 2392.00M | 2917.00M | 590.00M |
Total cash from operating activities | 2989.00M | 2633.00M | 4647.00M | 3539.00M | 3330.00M |
Issuance of capital stock | - | 0.00000M | 0.00000M | 2917.00M | 485.00M |
Depreciation | 2288.00M | 2229.00M | 2273.00M | 2154.00M | 2253.00M |
Other cashflows from investing activities | 158.00M | -177.00000M | -141.00000M | -421.00000M | -261.00000M |
Dividends paid | 1114.00M | 1082.00M | 1048.00M | 1026.00M | 984.00M |
Change to inventory | -15.00000M | -631.00000M | -104.00000M | -125.00000M | -149.00000M |
Change to account receivables | -290.00000M | 32.00M | -95.00000M | -48.00000M | -51.00000M |
Sale purchase of stock | 0.00000M | -500.00000M | -1750.00000M | 3389.00M | 2224.00M |
Other cashflows from financing activities | 1312.00M | 1796.00M | -265.00000M | -109.00000M | -205.00000M |
Change to netincome | - | 155.00M | -20.00000M | 372.00M | 215.00M |
Capital expenditures | 874.00M | 973.00M | 1231.00M | 810.00M | 957.00M |
Change receivables | - | 32.00M | -95.00000M | -48.00000M | - |
Cash flows other operating | - | 1180.00M | -515.00000M | 108.00M | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | -1485.00000M | -539.00000M | 2329.00M | - |
Change in working capital | -828.00000M | -1394.00000M | 282.00M | 512.00M | -143.00000M |
Stock based compensation | 259.00M | 233.00M | 237.00M | 244.00M | 261.00M |
Other non cash items | 362.00M | -94.00000M | 67.00M | 57.00M | 120.00M |
Free cash flow | 2115.00M | 1660.00M | 3416.00M | 2729.00M | 2373.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
BDX Becton Dickinson and Company |
-3.35 1.43% | 230.48 | 47.65 | 17.51 | 3.60 | 2.69 | 4.33 | 19.06 |
ISRG Intuitive Surgical Inc |
-1.89 0.50% | 373.12 | 76.39 | 50.76 | 16.72 | 9.14 | 16.12 | 52.74 |
ESLOY Essilor International SA |
-1.2204 1.11% | 108.48 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
ESLOF EssilorLuxottica Société anonyme |
-2.035 0.94% | 214.74 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
HOCPF HOYA Corporation |
- -% | 111.41 | 35.71 | - | 0.06 | 6.34 | 0.05 | 0.15 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
Name | Title | Year Born |
---|---|---|
Mr. Thomas E. Polen Jr. | Pres, CEO & Chairman | 1973 |
Mr. Christopher DelOrefice | Exec. VP & CFO | 1971 |
Mr. Samrat S. Khichi Esq. | Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel | 1967 |
Mr. Thomas J. Spoerel | Sr. VP, Controller & Chief Accounting Officer | 1978 |
Ms. Elizabeth McCombs | Exec. VP & Chief Technology Officer | 1976 |
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board | NA |
Ms. Denise Fleming | Exec. VP of Technology & Global Services and Chief Information Officer | NA |
Ms. Francesca M. DeMartino | Sr. VP & Head of Investor Relations | NA |
Michelle Quinn | Sr. VP and Chief Ethics & Compliance Officer | NA |
Troy Kirkpatrick | VP of PR | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).